Escitalopram is not considered entirely risk-free during pregnancy, but it is not clearly dangerous either. The decision to continue, stop, or switch medications involves weighing small but real risks from the drug against the well-documented harms of untreated depression during pregnancy. For many women, staying on escitalopram is the safer choice.
The Core Tradeoff: Medication vs. Untreated Depression
Untreated depression during pregnancy carries its own serious risks. Babies born to mothers with untreated depression face higher rates of premature birth, low birth weight, and restricted growth in the womb. Mothers themselves are more likely to develop preeclampsia, require hospitalization, and develop postpartum depression. Depression also increases the likelihood of smoking, poor nutrition, and substance use during pregnancy.
The relapse rate when stopping antidepressants is striking. In a large National Institutes of Health trial, 68% of women who discontinued their antidepressant during pregnancy experienced a major depressive relapse, compared with only 26% of those who stayed on medication. Women who stopped were three times more likely to be hospitalized with complications. This context matters when evaluating the relatively modest risks associated with escitalopram itself.
Heart Defect Risk in the First Trimester
The biggest structural concern with SSRIs (the drug class escitalopram belongs to) involves heart defects when taken during the first trimester, the period when the heart is forming. A meta-analysis of cohort studies found that first-trimester SSRI use was associated with a 26% relative increase in cardiovascular-related malformations. That sounds alarming, but the baseline rate of these defects is already low, so a 26% increase translates to a small absolute number of additional cases.
The most consistent finding involves atrial septal defects, essentially a small hole between the upper chambers of the heart. The relative risk for this specific defect was about double that of the general population. Ventricular septal defects, holes between the lower chambers, did not show a statistically significant increase. Many atrial septal defects close on their own or are correctable, but this is still a risk worth discussing with your provider, particularly if you’re in early pregnancy or planning to conceive.
Late Pregnancy: Breathing and Adjustment Issues
Taking escitalopram in the second half of pregnancy introduces two other concerns, both related to the baby’s transition at birth.
The first is a rare lung condition called persistent pulmonary hypertension of the newborn (PPHN), where a baby’s blood vessels don’t open properly after delivery. A 2018 meta-analysis of eight studies found that SSRI use during pregnancy increased the odds of PPHN by about 50%. But the absolute numbers are reassuring: the extra risk amounts to roughly 0.6 additional cases per 1,000 births, meaning about 1 in 1,615 exposed pregnancies would see this complication that wouldn’t have occurred otherwise. PPHN affects 1 to 2 babies per 1,000 births in the general population regardless of medication.
The second concern is poor neonatal adaptation, a cluster of symptoms that can appear in newborns shortly after delivery. These may include jitteriness, feeding difficulties, irritability, and respiratory distress. In one geographically defined cohort study, this affected 3% to 4% of exposed infants, with higher doses carrying greater risk. Symptoms are typically mild and resolve within days, but delivery teams should know about SSRI use so they can monitor the baby.
Neurodevelopmental Effects in Children
One area of growing research involves the long-term development of children exposed to escitalopram in the womb. A study published in Translational Psychiatry found that children prenatally exposed to escitalopram or its close relative citalopram had higher rates of ADHD diagnoses (7.5%) compared to unexposed controls (2.9%). ADHD symptom scores were also modestly elevated at ages 1.5 and 5 years. Some delays in communication and motor skills appeared in early assessments, though communication scores had equalized by age 5.
Interpreting these findings is tricky. Maternal depression itself affects child development, producing higher impulsivity, behavioral difficulties, and cognitive challenges. Separating the drug’s effect from the underlying condition is extremely difficult in observational research. The study noted that the marginal effects of escitalopram exposure were only statistically significant for ADHD symptoms, and even those effects were relatively small in absolute terms.
Your Body Processes the Drug Differently
Pregnancy changes how your body handles escitalopram in ways that matter clinically. Blood volume increases, liver enzymes speed up, and kidney filtration rises. By the third trimester, blood levels of escitalopram drop by roughly 44% compared to pre-pregnancy levels. After delivery, levels rebound quickly, reaching about 63% higher at 6 to 8 weeks postpartum than they were at 36 weeks of pregnancy.
This means a dose that worked before pregnancy may become inadequate as the pregnancy progresses. Pharmacokinetic modeling suggests that a 10 mg daily dose may fall below therapeutic levels for most women during pregnancy, while a 20 mg dose maintains adequate drug levels for more of the pregnancy, though even this can dip below target in the third trimester for some women depending on how quickly they metabolize the drug. If you notice your symptoms returning mid-pregnancy, a dose adjustment rather than a medication change may be all that’s needed.
The postpartum rebound also matters. A dose that was increased during pregnancy may become too high after delivery, so your provider will likely want to reassess within the first few weeks after birth.
Breastfeeding on Escitalopram
Escitalopram is generally considered one of the more compatible SSRIs for breastfeeding. The relative infant dose, a standard measure of how much drug a nursing baby receives, averages about 5.3% of the mother’s weight-adjusted dose. Anything under 10% is typically considered acceptable. In a study of nursing mothers taking escitalopram, the drug was undetectable in four out of five infant blood samples. The one infant with detectable levels had very low concentrations of 3 micrograms per liter, a fraction of what was present in the mother’s blood. No adverse effects were reported in the breastfed infants studied.
Putting the Risks in Perspective
No SSRI, including escitalopram, has been proven completely safe in pregnancy. But “not proven safe” is different from “known to be harmful.” The absolute risks are small: a modest increase in certain heart defects with first-trimester use, a very rare lung condition with late-pregnancy use, and a low rate of temporary adjustment symptoms in newborns. Neurodevelopmental signals exist but remain difficult to separate from the effects of depression itself.
On the other side of the scale, untreated moderate-to-severe depression reliably harms both mother and baby, and stopping medication leads to relapse in roughly two out of three women. For many, the math favors continuing treatment. The lowest effective dose is a reasonable goal, but undertreating depression to minimize a small medication risk can backfire. This is a decision best made with your prescriber, weighing the severity of your depression, your history of relapse, and how far along you are in pregnancy.